Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Catalog No. | Product Name | Size | List Price (US$) | Quantity |
---|
The manufacturing conditions of Avastin biosimilar from the CHO stable cell line need to be optimized by clients.
The cheapest research grade bevacizumab biosimilar protein (1 mg for >$30) is also available.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Bevacizumab (trade name Avastin, Genentech/Roche), the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.
Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
C001: Avastin Biosimilar Stable Cell Line (CHO)
The yield of Avastin biosimilar from the CHO stable cell line was above 1.7 g/L in a 750 liter manufacturing.
The Avastin stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.
Syd Labs also provides the following VEGF-A antibody biosimilar cell line:
Lucentis Biosimilar Cell Line (Fab produced in E. coli)
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.